Edition:
United Kingdom

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

4.00USD
18 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.00
Open
$4.10
Day's High
$4.15
Day's Low
$3.98
Volume
12,895
Avg. Vol
15,253
52-wk High
$11.70
52-wk Low
$3.35

Latest Key Developments (Source: Significant Developments)

Merrimack Pharmaceuticals - Expects to have about 27 employees after corporate restructuring - SEC filing
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS - EXPECTS TO HAVE ABOUT 27 EMPLOYEES AFTER CORPORATE RESTRUCTURING - SEC FILING.MERRIMACK PHARMACEUTICALS - TO INCUR EXPENSES RELATED TO RESTRUCTURING OF ABOUT $1.5 MILLION TO $1.8 MILLION FOR EMPLOYEE SEVERANCE, BENEFITS & RELATED COSTS.  Full Article

Merrimack Discontinues Phase 2 SHERLOC Study Of MM-121
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK DISCONTINUES PHASE 2 SHERLOC STUDY OF MM-121 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER DUE TO FUTILITY.MERRIMACK PHARMACEUTICALS INC - MM-121 DID NOT IMPROVE PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC).MERRIMACK PHARMACEUTICALS INC - IMPLEMENTING A COMPREHENSIVE REVIEW OF ITS DRUG CANDIDATE PIPELINE.MERRIMACK PHARMACEUTICALS INC - DECISION HAS BEEN MADE TO TERMINATE STUDY..MERRIMACK PHARMACEUTICALS INC - FUTILITY WAS OBSERVED, DECISION HAS BEEN MADE TO TERMINATE STUDY.MERRIMACK - DECISION WAS MADE FOLLOWING ANALYSIS THAT WAS TRIGGERED BY OCCURRENCE OF 75% OF EVENTS REQUIRED FOR TRIAL COMPLETION.MERRIMACK PHARMACEUTICALS INC - DECISION WAS MADE IN AGREEMENT WITH CHAIR OF INDEPENDENT DATA SAFETY MONITORING BOARD.MERRIMACK PHARMACEUTICALS INC - MM-121 IS ALSO CURRENTLY BEING EVALUATED IN SHERBOC STUDY.  Full Article

Merrimack Announces Top-Line Results From Randomized Phase 2 Trial Of MM-141
Monday, 25 Jun 2018 

June 25 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK ANNOUNCES TOP-LINE RESULTS FROM RANDOMIZED PHASE 2 TRIAL OF MM-141 IN FRONT-LINE METASTATIC PANCREATIC CANCER.MERRIMACK PHARMACEUTICALS INC - COMPANY CEASES DEVELOPMENT OF MM-141.MERRIMACK PHARMACEUTICALS INC - CARRIE STUDY DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS -.MERRIMACK PHARMACEUTICALS INC - CARRIE STUDY DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS.MERRIMACK PHARMACEUTICALS INC - CARRIE STUDY DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS.MERRIMACK PHARMACEUTICALS INC - CARRIE STUDY RESULTS WERE CONSISTENT IN ALL SUBGROUPS ANALYZED.  Full Article

Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Merrimack reports Q3 loss per share from continuing operations $0.40
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack reports third quarter 2017 financial results.Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40.Merrimack Pharmaceuticals-Believes unrestricted cash & cash equivalents & payments from shire will be sufficient to fund operations into H2 2019.  Full Article

Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer.Merrimack Pharmaceuticals - ‍orphan drug designation by FDA includes eligibility for 7-year period of marketing exclusivity for MM-121 upon approval​.Merrimack Pharmaceuticals - ‍MM-121 is currently being evaluated in SHERLOC study; top-line data for SHERLOC study is expected in H2 2018​.  Full Article

Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Merrimack Pharmaceuticals Inc ::Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020.Merrimack Pharmaceuticals-commenced tender offer to buy $25.03 million aggregate principal amount of outstanding 4.50 pct convertible senior notes due 2020​.  Full Article

Merrimack announces settlement of convertible note litigation
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack announces settlement of convertible note litigation.Merrimack Pharmaceuticals Inc - ‍agreement resolves outstanding litigation associated with Merrimack's asset sale to Ipsen​.Merrimack - ‍agrees to commence tender offer to purchase outstanding convertible notes with potential to eliminate all remaining debt​.Merrimack Pharmaceuticals Inc - Merrimack does not intend to declare an additional special dividend with any funds from escrow​.Merrimack-Under terms of settlement,co to pay noteholder plaintiffs $0.90 per $1.00 of convertible notes,plus accrued interest,an amount for legal fees​.Merrimack Pharmaceuticals -tender offer to acquire all remaining convertible notes at rate $0.90 per $1.00 of convertible notes, plus accrued interest​.Merrimack -‍settlement payout,amount co expects to pay for remaining notes,expenses related to Delaware action to be about $60 million released from escrow​.  Full Article

UPDATE 2-Ex-biopharmaceutical employees convicted in U.S. of insider trading

BOSTON, July 10 Two former employees of rival biopharmaceutical companies were convicted on Tuesday on U.S. charges that they used their access to confidential information about drug studies to profit in the stock market through insider trading.